|
|
| | Quinoline-15N, 98%) Basic information |
| Product Name: | Quinoline-15N, 98%) | | Synonyms: | CIPROFLOXACIN:HCL 100 ug/Ml in MeOH (2,3,Carboxyl-13C3, 99%;Quinoline-15N, 98%);CIPROFLOXACIN:HCL 100 UG/ML IN METHANOL (2,3,CARBOXYL-13C3, 99%;Ciprofloxacin hydrochloride-[13C3,15N;Ciprofloxacin·HCl (2,3,carboxyl-13C?, 99%;quinoline-1?N, 98%) 100 μg/mL in methanol | | CAS: | 2483830-12-0 | | MF: | C14C3H18FN2NO3·HCl | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Quinoline-15N, 98%) Structure]() |
| | Quinoline-15N, 98%) Chemical Properties |
| form | Solid | | color | White to off-white |
| | Quinoline-15N, 98%) Usage And Synthesis |
| Uses | Ciprofloxacin-13C3,15N (Bay-09867-13C3,15N) monohydrochloride is 13C- and 15N-labeled Ciprofloxacin (monohydrochloride) (HY-B0356A)[1]. | | in vivo | Isotopic labels can non-invasively track the distribution, transformation and clearance of compounds and their metabolites in the body through techniques such as mass spectrometry (MS) and nuclear magnetic resonance (NMR), which is beneficial to the study of pharmacometabolic kinetics (ADME).
Isotope labeling can reveal specific steps in metabolic pathways. Using compounds with stable isotope labels at specific locations directly in humans or animal models can also help verify drug mechanisms and evaluate unexpected side effects, improving the accuracy and efficiency of clinical research[3]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Smith K A, et al. Soil and environmental analysis[M]. Marcel Dekker Incorporated, 2000.
[3] Fan T W M, et al. Stable isotope-resolved metabolomics and applications for drug development[J]. Pharmacology & therapeutics, 2012, 133(3): 366-391. DOI:10.1016/j.pharmthera.2011.12.007 |
| | Quinoline-15N, 98%) Preparation Products And Raw materials |
|